The doctor is consulting the patient.

What is LucentAD® p-Tau 217

LucentAD® p-Tau 217 is used for the measurement of phosphorylated Tau 217 (p-Tau 217) which is a biomarker associated with amyloid pathology, a hallmark of Alzheimer’s disease.

Key Benefits

icon chart

Proven Biomarker

Demonstrated correlation with PET imaging and CSF biomarkers.

icon user

Non-Invasive

No lumbar puncture. No scan. Just a simple blood draw.

icon calender

Support for Your Practice

Easy onboarding and ongoing support to integrate into your workflow.

How LucentAD® p-Tau 217 Works

icon number one

Order the test

Easily request LucentAD® p-Tau 217 through our online provider portal or paper requisitions

icon number second

Blood Sample Collection

A simple blood draw at your practice or a partner lab

icon number three

Simoa® Analysis

Ultra-sensitive biomarker quantification

icon number four

Receive Results

Delivered within 10 business days for clinical interpretation

LucentAD® p-Tau 217

Special Instructions

This assay currently is not available in New York State

Expected Turnaround Time

10 business days

Related Documents

Sample Report

White Paper

The specialist is examining a blood test tube.

Clinical Validation and Supporting Research

  • Backed by leading Alzheimer’s research
  • Proven correlation with CSF and PET imaging for amyloid detection

Test specifications

Using and Interpreting the Results

Likelihood of Amyloid Pathology Interpretation

<0.040

Low likelihood of amyloid pathology. Other causes should be considered

0.041 – 0.089

Intermediate likelihood. Further testing (CSF/PET) may be required

>0.090

High likelihood of amyloid pathology. Consistent with Alzheimer’s disease

LucentAD® p-Tau 217 is not a standalone diagnostic test. It is meant to be used alongside clinical assessments for a comprehensive diagnostic evaluation.

Sample report